Trans fat reg
This article was originally published in The Tan Sheet
Executive Summary
FDA rule requiring disclosure of trans fat on nutrition labeling slated for FY 2003 completion, agency says following July 10 release of Institute of Medicine report on the substance. IOM panel finds "positive linear trend between trans fatty acid intake and total and LDL cholesterol concentration, and therefore increased risk" of coronary heart disease, "thus suggesting an [upper limit] of zero." However, achieving the suggested UL "would require extraordinary changes in patterns of dietary intake," IOM acknowledges. Consequently, report proposes no UL but recommends trans fat consumption "be as low as possible while consuming a nutritionally adequate diet"...
You may also be interested in...
Trans Fat Footnote Statement On Food, Supplement Labeling Proposed By FDA
FDA is seeking comments on the proposed use of a footnote statement on food and dietary supplement products containing trans fat that would advise consumers against excessive intake of the ingredient
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.